Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 274 No 7349 p573
14 May 2005

This article
Reprint   Photocopy

  Acrobat Reader


News summary


PCTs need clear point of contact at multiples

Primary care trusts need a clear point of contact at multiple pharmacies, Digby Emson, chairman of the Company Chemists’ Association, said at the Primary Care conference in Birmingham last week.

It is incumbent on multiples to make it as easy as possible for PCTs to engage with them, he argued, but PCTs also need to recognise that each multiple is different, and so be flexible and fair in their approach. “PCTs need to ensure that their commissioning arrangements are transparent and that they create a level playing field. This is crucial to every pharmacy contractor — both big and small,” he said.

Mr Emson also warned that community pharmacists need to recognise that, with regard to enhanced services, they are competing for the same funds as GPs and other primary care providers.

“We are going to have to make a strong case to attract funding and that will be a key role for local pharmaceutical committees,” he said.

CCA members should, therefore, support their LPC representatives, he said, so that they are able to do the best possible job of representing contractors’ interests with PCTs. “LPCs need to monitor local arrangements and ensure that pharmacy gets to hear about all the opportunities — whether they have a pharmacy label attached to them or not,” he added.

Independent and multiple pharmacies face many of the same problems and it is in the interests of both to present a united front to Government and commissioners of health services, he said. “Now that we have the contract and a model for fair funding for the future, community pharmacy not only has to deliver, but has also to be seen by the public to deliver,” he argued. “This obligation to deliver places an enormous pressure on us all — whether we are independent, single owner proprietors or the largest multiple.”

Back to Top


©The Pharmaceutical Journal